APM
TSHA icon

Avidity Partners Management’s Taysha Gene Therapies TSHA Stock Holding History

Avidity Partners Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-392,000
Closed -$10.4M – 124
2020
Q4 		$10.4M Hold
392,000
– – 0.34% 65
2020
Q3 		$8.78M Buy
+392,000
New +$9.22M 0.41% 47

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Avidity Partners Management's TSHA Position: Q1 2021 in Review

Avidity Partners Management sold out of Taysha Gene Therapies (TSHA) in Q1 2021, closing a stake of 392,000 shares — an estimated $10.4M sold.

Avidity Partners Management first reported a position in TSHA in Q3 2020 and held it in 2 quarters. The position peaked at $10.4M in Q4 2020. 46 funds tracked by Wall St. Rank hold TSHA as of Q1 2021.

  • Avidity Partners Management reported no remaining Taysha Gene Therapies position as of Q1 2021 after selling out during the quarter.
  • Avidity Partners Management sold 392,000 Taysha Gene Therapies shares in Q1 2021, an estimated $10.4M.
  • Avidity Partners Management first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 2 quarters.
  • Avidity Partners Management's Taysha Gene Therapies position peaked at $10.4M in Q4 2020.
  • 46 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2021.

Based on Avidity Partners Management's 13F filing for Q1 2021, filed 17 May 2021.